Last reviewed · How we verify
NCT04982146
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
Phase 1 trial testing Bromelin in Pseudomyxoma Peritonei in 10 participants. Status unknown.
16 May 2022
Quick facts
| Lead sponsor | Maimónides Biomedical Research Institute of Córdoba |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 13 September 2021 |
| Primary completion | 16 May 2022 |
| Estimated completion | 16 May 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Bromelin — full drug profile →
- N-Acetylcysteine — full drug profile →
Conditions studied
- Pseudomyxoma Peritonei — all drugs for Pseudomyxoma Peritonei →
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Who can join
18 and older, any sex, with Pseudomyxoma Peritonei. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Linking Iron Metabolism, Ferroptosis, and Cancer: New Targets and Prospects for Effective Anticancer Therapeutic Interventions.
Kourti M, Kontoghiorghes GJ. · · 2026 · PMID 42122232 · DOI 10.3390/cancers18091436
Verify or expand the search:
- PubMed search for NCT04982146
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pseudomyxoma Peritonei
Currently open trials in the same condition.
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07341360 — Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei · EARLY_PHASE1 · recruiting
- NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
Other Maimónides Biomedical Research Institute of Córdoba trials
Trials by the same sponsor.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07479303 — Vitamin D Status in Young Medical Residents · completed
- NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
- NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
- NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04982146 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
- Last refreshed: 2 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982146.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing